EFFECTS OF ARONIA MELANOCARPA JUICE ON PLASMA AND LIVER PHOSPHOLIPID FATTY ACID COMPOSITION IN WISTAR RATS

ZEC Manja1, DEBELJAK MARTAČIĆ Jasmina1, RANKOVIĆ Slavica1, POKIMICA Biljana1, TOMIĆ Mirko2, IGNJATOVIĆ Đurdica2, GLIBETIĆ Maria1, POPOVIĆ Tamara1*

1Center of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, University of Belgrade; 11000 Belgrade, Serbia; 2Institute for Biological Research “Siniša Stanković”, University of Belgrade; 11000 Belgrade, Serbia

(Received 20 July 2016, Accepted 29 December 2016)

A nutritional placebo-controlled study was performed in Wistar rats in order to investigate the effects of 5-weeks aronia juice consumption towards fatty acid (FA) composition of phospholipids in the plasma and liver, as well as plasma glucose (Glu) and cholesterol levels. The animals were divided into 3 groups of 8 animals each, and randomized to receive either the full polyphenol dose of Aronia melanocarpa juice (AMJ), 4 times less polyphenol dose (¼-AMJ) or polyphenol-lacking placebo beverage (PLB). Each group of 8 male adult Wistar rats received the liquid ad libitum. AMJ decreased the levels of low-density lipoprotein (LDL) (P < 0.05) vs. PLB. AMJ increased dihomo-γ-linoleic acid (DGLA, 20:3n-6) (P < 0.05) and decreased arachidonic acid content (AA, 20:4n-6) (P < 0.05) vs. PLB in liver phospholipids. AMJ significantly increased monounsaturated fatty acids (MUFA) levels both in the liver (P < 0.05) and plasma (P < 0.05). Both aronia juice doses elevated the levels of beneficial n-3 polyunsaturated fatty acids (PUFA) in the plasma and liver. There was a dose-dependent, significant increase (P < 0.001) in cis-vaccenic acid (VA, 18:1n-7) in phospholipids in the plasma and liver. Our results indicate favorable effects of aronia juice intake on lipid parameters in Wistar rats. These findings suggest the potential of aronia dietary intake in cardiometabolic diseases primary prevention strategies in the human population.

Key words: chokeberry, polyphenols, low-density lipoprotein, arachidonic acid, monounsaturated fatty acids

INTRODUCTION

Aronia melanocarpa (AM), a berry fruit, has been scientifically investigated for a wide array of health-promoting characteristics. The beneficial properties of AM on health are attributed to the high content of non-nutritional phytochemicals i.e. polyphenols [1,2], both flavonoid and non-flavonoid subclasses. Beneficial effects of polyphenol
intake have been studied thoroughly [3,4], mostly in the context of chronic disease prevention.

Fatty acids (FA) are stored at different rates in different tissues [5,6], thus potentially influencing particular tissue metabolism. The phospholipid FA composition and cholesterol content are basic determinants of the physical properties of biomembranes. They have been shown to influence a wide variety of membrane dependent functions such as membrane transport, enzyme activity and receptor function [7]. The FA profile in tissues partly reflects not only the dietary fat intake, but also the efficiency of FA metabolism in the body [8]. The liver has an important role in the synthesis and metabolism of phospholipids. Liver phospholipids are a building structure of the hepatocyte membrane, they take part both in metabolic activities and repairing after metabolic disturbances [9].

Recently, rat animal models have been exploited for the investigation of the protective effects of consumption of AM polyphenols towards the accumulation of xenobiotics in soft animal tissues [10]. However, a limited number of available studies deals with the biological effects of AM consumption regarding cardio metabolic biomarkers in rats. Existing preclinical data indicate anti-oxidative [11,12], hypotensive [13], lipid-lowering [1,14] and glucose-regulating [15] effects in rats treated with AMJ. There is a limited number of studies dealing with the polyphenol-rich diet impact on lipid and FA status in rodent models [16,17]. So far, none of the studies has investigated the biological effect of polyphenols contained in AMJ towards FA tissue content in rats. In addition, none of the available animal studies investigated the dose-response biological effects of aronia juice towards the status of phospholipids FA content in tissues.

We challenged the beneficial effects of aronia juice long-term consumption in rats on phospholipid plasma and liver FA composition, as well as on some biochemical parameters. Additionally, we evaluated the dose-dependent effect of consumption of aronia juice containing different polyphenol doses.

**MATERIALS AND METHODS**

**Study design and study treatments**

The animals underwent a parallel, nutritional, placebo-controlled study. The animals were fed for 5-weeks with either one of the 3 protocols: 2 doses of aronia juice (“Nutrika”, Belgrade, Serbia), and PLB. PLB was synthesized to contain the exact nutritional values as aronia juice, including sugars, minerals and vitamins, but without bioactive polyphenols (N. Kardum, unpublished data). The aronia juice treatment was applied in 2 polyphenol doses: full polyphenol dose (AMJ) and a dose with exactly the same chemical composition as AMJ but with 4 times less polyphenol content (¼-AMJ). All of the comparisons in the study were performed between animals receiving either of 2 polyphenol doses of aronia juice versus control animals receiving the placebo.
Characterization of the intervention treatments

Analysis of phenolic compounds in AMJ was determined using a modified Folin-Ciocalteu method [18]. Beverage samples were diluted in distilled water to working solutions in order for absorbencies to fit the standard calibration curve in the range of 0-600 μg/ml of gallic acid. Results were expressed as micrograms of gallic acid equivalents per ml of beverage, and data are presented as mean ± SD for 3 replicates. The polyphenol content of the study interventions is presented (Table 1) and quantities of phenolic compounds in AMJ were presented by Tomić et al. [19].

Table 1. Aronia juice polyphenol content

<table>
<thead>
<tr>
<th>Content(mg/100 mL)</th>
<th>AMJ</th>
<th>¼-AMJ</th>
<th>PLB</th>
</tr>
</thead>
<tbody>
<tr>
<td>1177.11</td>
<td>294.28</td>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

Animals

Male, adult, 4-months old, Wistar rats, weighing 380–440 g, provided by the vivarium of the Institute for Biological Research, Belgrade, Serbia, were used in this study. The animals were kept in groups of 4 per cage, under controlled conditions (room temperature 23–25°C, 12 h light–dark cycle, food and drinking liquid ad libitum). All animal procedures were in compliance with Directive 2010/63/EU on the protection of animals used for experimental and other scientific purposes, and approved by the Ethical Committee for the Use of Laboratory Animals of the Institute for Biological Research “Siniša Stanković”, University of Belgrade.

The animals were randomly assigned into 3 experimental groups of 8 animals each, to receive either AMJ, ¼-AMJ or PLB, supplied with 20% mixture (m/m) of experimental beverage in tap water. Fresh drinking solutions were prepared daily. The rats were fed standard briquettes including a commercial non purified diet (Veterinarski Zavod, Subotica, Serbia), containing (w/w) 20% protein, 40% carbohydrates, 5% fat, fiber 8%, and an adequate amount of vitamins and minerals (ash 10%). 1 gram represented an estimated metabolic energy of 11 kJ with 17.09% derived from fat. The FA composition of the supplied standard briquettes was: 18.91% SFA, 29.24% MUFA and 52.9% PUFA.

Experimental drinking solutions were offered ad libitum for 35 days. The body mass of the rats was registered on days: -1, 7, 14, 21, 28 and 35, and presented as mean value ± SEM for each experimental group on the experiment weeks: 0-5 (Figure 1a). There was no statistical difference between body mass of animals between the different treatment groups on day -1 and before sacrifice on day 35 (P > 0.05 for both measurements, data not shown). Daily consumption of drinking solutions was estimated for each group, and their average weekly consumption in ml of solution per
animal/day are presented in Figure 1b. Food consumption per cage was estimated 3 times a week and described as g of food/animal/day of every week of the experiment (Figure 1c). According to the determined polyphenol content, we have calculated the daily average intake of polyphenols to be 557.22 and 120.64 mg per ml of treatment for AMJ and 1/4-AMJ groups, respectively (Figure 1d).

Figure 1. Body mass and daily consumption. (a) changes in body mass; (b) consumption of either of 3 treatments; (c) food consumption; (d) daily polyphenol expenditure. The graphs are represented per 3 groups of animals (receiving either AMJ, 1/4-AMJ or PLB) for (a), (b) and (c). The (d) is grouped per animals receiving either AMJ or 1/4-AMJ treatment. All values are plotted as mean±SEM (a, b, c), and daily mean value (d).

Sampling and biochemical analyses

On day 35 upon treatment, all animals were sacrificed by cardiac puncture under anesthesia, and blood samples were collected for biochemical and laboratory analysis. Blood samples (6–8 cm³) from all rats were collected by aorta abdominalis puncture in Na-citrate containing (3.8% w/v) tubes, and plasma samples were collected upon centrifugation. Liver samples were stored at -80°C. Biochemical parameters were determined from the plasma using standard laboratory kits on Cobas c-111 biochemical analyzer (Roche, Basel, Switzerland).

Preparing liver tissue for phospholipids FA analysis and lipid extraction

The liver tissue (1 g) was homogenized with a 2:1 chloroform/methanol mixture with butylated hydroxytoluene (BHT) as an antioxidant and washed with 5 times less
volume of water. The resulting mixture separated into two phases, the lower phase yielding the total pure lipid extract. Further evacuation was done with 2:1 solvent systems: methanol/benzene, acetone/benzene, and ethanol/benzene. Upon adding and evacuation of chloroform and adding hexane afterwards, samples were ready for thin layer chromatography (TLC) [20].

**FA analysis in the liver tissue**

The phospholipid fraction was isolated from the extracted lipids by one-dimensional TLC with the neutral lipid solvent system of petrol ether-diethyl ether-acetic acid (87:12:1, v/v) using Silica Gel GF plates (C. Merck, Darmstadt, Germany). The extraction and preparation of FA methyl esters and their gas chromatography analyses were performed as previously described [9]. Briefly, FA methyl-ester derivatives formed from isolated plasma phospholipids fraction were separated by gas chromatography using Shimadzu GC 2014 (Shimadzu Co, Tokyo, Japan) equipped with a flame ionization detector and Rtx 2330 fused silica gel capillary column (60 m x 0.25 mm x 0.2 μm) (Restek Co, Bellefonte, PA, USA). The flame ionization detector was set at 250°C, the injection port at 220°C, and the oven temperature programmed from 130 to 190°C at heating rate of 3°C/min. Comparing sample peak retention times with authentic standards (Sigma Chemical Co, St. Louis, MO, USA) and/or the PUFA-2 standard mixture (Supelco Inc., Belleforte, PA, USA), individual FA methyl esters were identified [21].

**Lipid extraction and plasma phospholipids FA analysis**

The total lipid extract was prepared by the method described by Folch [21]. The phospholipid fraction was isolated as indicated. The extraction and preparation of FA methyl esters and their gas chromatography analyses were performed as indicated. The identification of FA methyl esters was made by comparing sample peak retention times with authentic standards (PUFA-2 and/or 37 FAMEs mix, Supelco, Bellefonte, PA, USA) [22]. Finally, individual FA starting from palmitic acid (PA, 16:0) through docosahexaenoic acid (DHA, 22:6 n-3) were expressed as a percent in total identified FA.

**Statistical analysis**

The results are presented as mean ± SD. The differences between the groups were calculated by one-way Analyses of Variance (One-way ANOVA) followed by Tukey’s Post Test of individual significant differences between the groups. Analysis was performed using the SPSS software (ver. 15.0; Chicago, IL), and the level of significance was set at P < 0.05.

The sample size was calculated according to data on chokeberry effects on plasma cholesterol fractions content previously reported [23]. With statistical power set at 80% (β = 0.80) and P value of 0.05, the required number of animals was minimum 7 per group.
RESULTS

Biochemical parameters

LDL fraction was decreased in the group receiving AMJ compared to the control group receiving PLB (P = 0.021) (Table 2).

Table 2. Biochemical parameters in control (PLB) and treated animals (¼-AMJ or AMJ)

<table>
<thead>
<tr>
<th></th>
<th>Control (n=8)</th>
<th>¼-AMJ (n=8)</th>
<th>AMJ (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC [mmol/L]</td>
<td>0.91±0.09</td>
<td>1.05±0.10</td>
<td>0.96±0.17</td>
</tr>
<tr>
<td>Glu [mmol/L]</td>
<td>8.94±1.35</td>
<td>9.61±3.62</td>
<td>7.31±1.27</td>
</tr>
<tr>
<td>HDL [mmol/L]</td>
<td>0.78±0.08</td>
<td>0.72±0.09</td>
<td>0.70±0.10</td>
</tr>
</tbody>
</table>
| LDL [mmol/L]    | 0.12±0.03    | 0.14±0.04   | 0.09±0.03*#
| TAG [mmol/L]    | 0.72±0.14    | 0.96±0.16   | 0.99±0.44 |

Level of significant difference upon ANOVA. *compared to control group; #comparison between groups P <0.05. Data are presented as mean±SD. TC-total cholesterol; GLU-glucose; HDL-high-density lipoprotein; LDL-low-density lipoprotein; TAG-triglyceride.

The changes in plasma phospholipids FA composition upon 5-weeks placebo-controlled aronia intervention

There was a significant, dose-dependent increase in plasma VA content in aronia-receiving animals in comparison with PLB-receiving animals (P = 0.039, P = 0.003, for ¼-AMJ and AMJ, respectively). A statistically significant increase was observed for total plasma MUFA in animals on either AMJ or ¼-AMJ, in comparison with animals on PLB (Table 3), which was more pronounced in the AMJ group (P = 0.017), than in ¼-AMJ (P = 0.042).

Table 3. Plasma phospholipid fatty acid content in control (PLB) and treated animals (¼-AMJ and AMJ)

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 8)</th>
<th>AMJ (n = 8)</th>
<th>¼-AMJ (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:0</td>
<td>24.57 ± 0.76</td>
<td>24.25 ± 1.45</td>
<td>23.38 ± 1.49</td>
</tr>
<tr>
<td>18:0</td>
<td>22.06 ± 0.82</td>
<td>21.56 ± 1.48</td>
<td>21.79 ± 1.20</td>
</tr>
<tr>
<td>SFA</td>
<td>46.63 ± 0.83</td>
<td>45.80 ± 2.66</td>
<td>45.17 ± 2.18</td>
</tr>
<tr>
<td>16:1</td>
<td>0.43±0.06</td>
<td>0.46±0.12</td>
<td>0.41±0.15</td>
</tr>
<tr>
<td>18:1n-9</td>
<td>3.95±0.63</td>
<td>4.47±0.46</td>
<td>4.55±0.42</td>
</tr>
<tr>
<td>18:1n-7</td>
<td>2.66±0.22</td>
<td>3.34±0.48**</td>
<td>3.14±0.33*</td>
</tr>
<tr>
<td>MUFA</td>
<td>7.04±0.74</td>
<td>8.28±0.93*</td>
<td>8.10±0.76*</td>
</tr>
</tbody>
</table>
Changes in liver phospholipids FA composition

The same as for plasma phospholipids, the levels of VA were significantly increased in animals upon aronia juice exposure in a dose-dependent way, especially pronounced in the case of AMJ (P = 0.001), in comparison with levels of VA in control animals. Oleic acid (OA, 18:1n-9) followed the same increasing trend, which consequently led to a significant increase in total MUFA levels in liver phospholipids (Table 4), again in a dose-dependent fashion, AMJ (P = 0.023) versus PLB.

Upon polyphenol treatment there was a dose-dependent decrease in stearic acid (SA, 18:0) in liver phospholipids (P = 0.01, P = 0.005, for ¼-AMJ and AMJ, respectively) compared to PLB treatment (Table 4).

Both aronia treatments increased the percentage of docosapentaenoic acid (DPA, 22:5n-3) (P = 0.076, P = 0.049, for AMJ and ¼-AMJ, respectively). Additionally, there was a significant increase in n-3 PUFA (P = 0.053) upon AMJ treatment, compared to PLB treatment (Table 4).

In comparison with the control level, the level of AA, upon 5-week consumption of AMJ was significantly decreased (P = 0.05) in liver phospholipids (Table 4). Also, there was an increase in the percentage of DGLA (P = 0.05) in AMJ group compared to PLB group (Table 4).
Table 4. Liver phospholipid fatty acid content in control (PLB) and treated animals (¼-AMJ and AMJ).

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 8)</th>
<th>AMJ (n = 8)</th>
<th>¼-AMJ (n = 8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:0</td>
<td>19.91±0.57</td>
<td>20.52±0.91</td>
<td>21.01±1.21</td>
</tr>
<tr>
<td>18:0</td>
<td>22.24±0.93</td>
<td>20.70±0.51</td>
<td>20.78±0.88*</td>
</tr>
<tr>
<td>SFA</td>
<td>42.15±0.83</td>
<td>41.22±0.98</td>
<td>41.79±1.07</td>
</tr>
<tr>
<td>16:1</td>
<td>0.57±0.12</td>
<td>0.59±0.15</td>
<td>0.55±0.11</td>
</tr>
<tr>
<td>18:1n-9</td>
<td>3.10±0.50</td>
<td>3.19±0.29</td>
<td>3.19±0.34</td>
</tr>
<tr>
<td>18:1n-7</td>
<td>2.68±0.25</td>
<td>3.50±0.48***</td>
<td>3.13±0.31</td>
</tr>
<tr>
<td>MUFA</td>
<td>6.35±0.57</td>
<td>7.29±0.72*</td>
<td>6.87±0.44</td>
</tr>
<tr>
<td>18:2n-6</td>
<td>15.99±1.85</td>
<td>16.33±0.96</td>
<td>16.59±1.09</td>
</tr>
<tr>
<td>20:3n-6</td>
<td>0.90±0.15</td>
<td>1.08±0.10*</td>
<td>1.01±0.14</td>
</tr>
<tr>
<td>20:4n-6</td>
<td>25.65±1.23</td>
<td>24.08±1.26*</td>
<td>24.06±1.02</td>
</tr>
<tr>
<td>20:5n-3</td>
<td>0.69±0.18</td>
<td>0.79±0.14</td>
<td>0.80±0.15</td>
</tr>
<tr>
<td>22:4n-6</td>
<td>0.27±0.02</td>
<td>0.30±0.03</td>
<td>0.26±0.03</td>
</tr>
<tr>
<td>22:5n-3</td>
<td>1.09±0.14</td>
<td>1.26±0.14*</td>
<td>1.28±0.12*</td>
</tr>
<tr>
<td>22:6n-3</td>
<td>7.26±0.63</td>
<td>7.64±0.54</td>
<td>7.34±0.39</td>
</tr>
<tr>
<td>PUFA</td>
<td>51.84±0.93</td>
<td>51.48±1.28</td>
<td>51.35±0.75</td>
</tr>
<tr>
<td>n-6</td>
<td>42.81±1.33</td>
<td>41.79±1.54</td>
<td>41.92±1.08</td>
</tr>
<tr>
<td>n-3</td>
<td>9.03±0.68</td>
<td>9.69±0.45*</td>
<td>9.43±0.43</td>
</tr>
<tr>
<td>n-6/n-3</td>
<td>4.77±0.47</td>
<td>4.32±0.33</td>
<td>4.46±0.30</td>
</tr>
<tr>
<td>Omega-3-Index</td>
<td>7.94±0.65</td>
<td>8.43±0.44</td>
<td>8.15±0.36</td>
</tr>
<tr>
<td>AA/EPA</td>
<td>40.15±12.68</td>
<td>31.42±6.93</td>
<td>31.08±7.60</td>
</tr>
</tbody>
</table>

Level of significant difference upon ANOVA followed by Tukey’s Post Hoc multiple comparison test. *P <0.05; **P <0.01; ***P <0.001. Data are presented as % of fatty acids in the total pool. SFA-totalsaturated fatty acids; MUFA-totalmonounsaturated fatty acids; PUFA-polyunsaturated fatty acids; Omega-3-Index-EPA+DHA.

DISCUSSION

One of the greatest advantages of the study described herein is the application of an intermediate treatment dose. Three different treatments were applied (placebo beverage, and two doses of aronia juice differing in polyphenol content) to three groups of animals, thus enabling the evaluation of a polyphenol dose-dependent effect on the lipid status. Our results indicated the favorable effect of aronia juice consumption regarding lipid classes including LDL and FA phospholipids in the plasma and liver. The novelty of this work is the investigation of a dose-dependent biological effect of polyphenol-rich aronia juice towards endogenous tissue phospholipid FA status in rats.
AMJ had a favorable decreasing effect on LDL level, while ¼-AMJ showed the opposite (Table 2). The exactly same trend, but without statistical significance, was observed in Glu level upon treatment with two polyphenol doses of aronia juice in comparison to the control. The hypocholesterolemic effect of aronia polyphenols was previously demonstrated in rats with experimentally induced hyperlipidemia [1,23,24]. The hypoglycemic effect of aronia incorporated into drinking water was observed in diabetic and normal rats upon intraperitoneal administration [25].

The postulated protective, lipid-lowering effects of high polyphenol doses in AMJ, might account for the LDL decrease in the sub-cohort of animals receiving AMJ. Qin and Anderson [15] have reported similar results, demonstrating a beneficial metabolic shift in fructose fed rats receiving the aronia extract in comparison with those on the fructose diet solely.

Aronia juice consumption exerted a consistent biological effect on rat plasma and liver phospholipid FA profiles, upon 5-weeks of aronia treatment. Upon treatment with both doses of aronia juice, and in comparison with the control animals receiving PLB, there was an increase in OA, VA, and total MUFA levels, both in the plasma and liver. OA has anti-atherogenic and antithrombotic properties and increases HDL to LDL ratio. Incorporation of OA into cholesterol esters, triglycerides and phospholipids of lipoprotein particles reduce lipoprotein oxidation. Incorporated into membrane lipids, OA regulates the fluidity of the cell membrane, the efficiency of transmembrane transport and affects signal transduction [26].

The dose-dependent increase in VA and MUFA levels was statistically significant, which indicates the additive effect of polyphenol content, in both tissues.

Studies dealing with the health implications of cis-VA status are scarce. An interesting finding indicates an unfavorable association of reduced levels of VA in plasma and liver of hypertensive rats with the incidence of stroke-like metabolic features [27]. The inverse association of cis-VA has been demonstrated in human studies investigating the correlation of its content in red blood cells and plasma with the incidence of myocardial infarction and heart failure with antecedent coronary heart disease, respectively [28,29]. Accordingly, the current finding indicates the potentially favorable effect of aronia juice through the elevation of cis-VA plasma and liver content.

The decrease in SFA is dose/dependent in liver phospholipids, and may be indicative of AMJ protective effects because long-chain SFA are speculated to induce pro-inflammatory responses [30] and apoptosis of different vascular cell types [31].

The herein reported decrease in SFA in both tissues additionally indicates aronia-protective effects, especially since it is coupled with the aronia-induced statistically significant increase in MUFA levels, contemplated to be associated to beneficial inflammatory properties [32].

Also, DGLA that was increased in the liver upon AMJ treatment exert anti-inflammatory properties [33]. We have reported a dose-dependent decline in AA level,
in both tissues, that contributed to the dose-dependent decrease in overall n-6 PUFA. It is well known that AA is further metabolized to potent inflammatory eicosanoids. Additionally, both in the liver and plasma, there was an increase in EPA, DPA and DHA levels upon both polyphenol aronia doses, followed by a dose-dependent increase in total n-3 PUFA level, Omega-3-Index, as well as decrease in n-6/n-3 ratio. In contrast to n-6 PUFA, n-3 PUFA exert hypolipidemic, vasodilatory, antithrombotic, and anti-inflammatory properties [34].

We demonstrated an increase in Omega-3-Index (EPA + DHA content) and a decrease in AA to EPA ratio upon aronia juice consumption. Since the Omega-3-Index is inversely [35], and AA/EPA ratio directly associated with CVD risk [36], the results indicate additional aronia-juice cardio-protective effects.

Available exploratory preclinical research data on AM health effects [11-14] support our findings. Thus, consumption of aronia juice or chokeberry extract incorporated in the standard diet, has shown health-promoting properties in experimental rodent models, including rat models of arterial hypertension [13], hyperlipidemia [1], metabolic syndrome [14], and glucose metabolic disorders which preferentially lead to diabetes [15]. Additionally, the pretreatment with aronia in laboratory rats has shown anti-oxidative effects in the case of diet- [12,37] and chemically [11] induced oxidative stress. Observed beneficial effects are attributed to the bioactivity of polyphenols. We postulated a polyphenol dose-dependent cardio-protective effect in rats, through the balancing of crucial fatty acid classes: increase in MUFA and n-3 PUFA levels, as well as an overall decline in the levels of saturated fats. Possible background of polyphenol bioactivity towards lipid metabolism is discussed in the available literature. In addition to the adipocyte cell cycle disruption, lipido-protective mechanisms for polyphenol dietary intake include several pathways: inhibition of de novo lipogenesis, lipolysis promotion, fatty acid β-oxidation promotion, as well as different anti-inflammatory mechanisms coupled with balancing of intracellular and intra-tissue oxidative stress and insulin sensitivity improvement [38].

We concluded a dose-dependent beneficial effect of aronia juice consumption on LDL and plasma and liver phospholipids fatty acid profiles in aronia-treated Wistar rats. The implications from the current pre-clinical study in phospholipids FA profiles are to be confirmed in large-scale clinical trials, encompassing both healthy and at-risk, disease-free populations.

Acknowledgments

This work was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, under Grant number III41030. The authors are grateful to “Nutrika” Company, Belgrade, Serbia.
Authors’ contributions

ZM drafted the manuscript and performed the statistical analysis. DMJ, RS and PB carried out the analysis and interpretation of data as well as revising the manuscript critically for important intellectual content. ID carried out the analysis. GM and TM have made substantial contributions to conception and design. PT carried out the analysis and interpretation of data as well as revising the manuscript critically for important intellectual content and have given final approval of the version to be published. All authors read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES


EFEKAT ARONIJE (Aronia melanocarpa) NA MASNOKISELINSKI PROFIL FOSFOLIPIDA PLAZME I JETRE PACOVA WISTAR SOJA

ZEC Manja, DEBELJAK MARTAČIĆ Jasmina, RANKOVIĆ Slavica, POKIMICA Biljana, TOMIĆ Mirko, IGNJATOVIĆ Đurđica, GLIBETIĆ Maria, POPOVIĆ Tamara

Na pacovima Wistar soja je uradjena nutritivna placebo-kontrolisana studija sa ciljem da se ispituju efekti suplementacije sokom od aronije, u trajanju od pet nedelja, na masno-kiselinski profil fosfolipida plazme i jetre, kao i na nivoе glukoze i holesterola u plazmi. Životinje su podeljene u tri grupe od po osam životinja. Životinje su randomizirane tako da budu na jednom od tri tretmana: sok od aronije sa punom dozom polifenola (AMJ), sok od aronije sa четiri puta manjom dozom polifenola (1/4 AMJ) ili placebo (sok bez polifenola) (PLB). Svaka grupa odraslih mužjaka pacova Wistar soja je dobijala tečnost ad libitum. AMJ tretman je uticao na sniženje nivoе lipo-proteina niske gustine (LDL, P<0,05) u odnosу на PLB. AMJ tretman je uticao на pove¢anje dihomo-γ-linolenske kiseline (DGLA, 20:3n-6, P<0,05), kao и на smanjenje nivoа arahidonske kiseline (AA, 20:4n-6, P<0,05) u odnosу на placebo у fosfolipidima jetre. Tretman sokom од aronije sa visokom dozom polifenola je zna¢ajno pove¢ao mononezasi¢ene masne kiseline (MUFA), kako у fosfolipidima jetre (P<0,05), тако и у fosfolipidima plazme (P<0,05). Obe doze soka од aronije су zna¢ajno pove¢ale nivo korisних n-3 polinezasi¢ених masних kisilina (PUFA) у plazmi и jetri. Uo¢eno je и dozno zavisno zna¢ajno pove¢anje cis-vakcenske kiseline (VA, 18:1n-7, P<0,001) у fosfolipidima plazme и jetre. Naši rezultati ukazuju на korisne efekte soka од aronije на lipidne parametre kod pacova Wistar soja. Ovakvi nalazi sugerisu moguћnost da unos soka од aronije može bitи од koristi у strategijama primarne prevencije kardiovaskularних oboljenja у humanoj populaciji.